128 related articles for article (PubMed ID: 38615670)
1. Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis.
Chen C; Zhu Y; Zhang H; Xiao L
Gynecol Obstet Invest; 2024 Apr; ():1-13. PubMed ID: 38615670
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.
Sheng X; Guo Y; Lu Y
Medicine (Baltimore); 2017 Jul; 96(28):e7476. PubMed ID: 28700487
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
[TBL] [Abstract][Full Text] [Related]
5. The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.
Jiang Y; Cui L; Chen WD; Shen SH; Ding LD
PLoS One; 2012; 7(5):e36780. PubMed ID: 22615811
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylations of RASSF1A and p16 is associated with clinicopathological features in lung cancers.
Han JC; Xu F; Chen N; Qi GB; Wei YJ; Li HB; Zhang YJ; Li JH; Wang XL; Xu W; Li XF; Jin LF; Jia JY; Ma ZS
J Cancer Res Ther; 2016; 12(1):340-9. PubMed ID: 27072261
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Kalachand RD; Stordal B; Madden S; Chandler B; Cunningham J; Goode EL; Ruscito I; Braicu EI; Sehouli J; Ignatov A; Yu H; Katsaros D; Mills GB; Lu KH; Carey MS; Timms KM; Kupryjanczyk J; Rzepecka IK; Podgorska A; McAlpine JN; Swisher EM; Bernards SS; O'Riain C; O'Toole S; O'Leary JJ; Bowtell DD; Thomas DM; Prieske K; Joosse SA; Woelber L; Chaudhry P; Häfner N; Runnebaum IB; Hennessy BT
J Natl Cancer Inst; 2020 Dec; 112(12):1190-1203. PubMed ID: 32413141
[TBL] [Abstract][Full Text] [Related]
8. Methylation status of the
Matthaios D; Balgkouranidou I; Karayiannakis A; Bolanaki H; Xenidis N; Amarantidis K; Chelis L; Romanidis K; Chatzaki A; Lianidou E; Trypsianis G; Kakolyris S
Oncol Lett; 2016 Jul; 12(1):748-756. PubMed ID: 27347211
[TBL] [Abstract][Full Text] [Related]
9. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
[TBL] [Abstract][Full Text] [Related]
10. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
[TBL] [Abstract][Full Text] [Related]
11. RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis.
Zheng F; Yu H
Arch Gynecol Obstet; 2018 Feb; 297(2):467-477. PubMed ID: 29288321
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of RASSF1A methylation status in non-small cell lung cancer (NSCLC) patients: A meta-analysis of prospective studies.
Hu H; Zhou Y; Zhang M; Ding R
Biomarkers; 2019 May; 24(3):207-216. PubMed ID: 30764677
[No Abstract] [Full Text] [Related]
13. ABERRANT METHYLATION OF CANCER-RELATED GENES IN VIETNAMESE BREAST CANCER PATIENTS: ASSOCIATIONS WITH CLINICOPATHOLOGICAL FEATURES.
Dieu Vuong L; Ngoc Nguyen Q
Exp Oncol; 2023 Oct; 45(2):195-202. PubMed ID: 37824772
[TBL] [Abstract][Full Text] [Related]
14. Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.
Shi H; Li Y; Wang X; Lu C; Yang L; Gu C; Xiong J; Huang Y; Wang S; Lu M
PLoS One; 2013; 8(10):e76787. PubMed ID: 24116157
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis.
Wu L; Wang F; Xu R; Zhang S; Peng X; Feng Y; Wang J; Lu C
Breast Cancer Res Treat; 2013 Dec; 142(3):619-27. PubMed ID: 24258259
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
Wang J; Wang B; Chen X; Bi J
Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
[TBL] [Abstract][Full Text] [Related]
18. Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.
Wang HL; Zhang Y; Liu P; Zhou PY
Mol Biol Rep; 2014 Jun; 41(6):3991-9. PubMed ID: 24566684
[TBL] [Abstract][Full Text] [Related]
19. Gene promoter methylation is associated with increased mortality among women with breast cancer.
Xu X; Gammon MD; Zhang Y; Cho YH; Wetmur JG; Bradshaw PT; Garbowski G; Hibshoosh H; Teitelbaum SL; Neugut AI; Santella RM; Chen J
Breast Cancer Res Treat; 2010 Jun; 121(3):685-92. PubMed ID: 19921426
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis demonstrates no association between p16
Jiang Y; Yan F; Liang L; Wan Y; Liu J; Cheng W
Arch Gynecol Obstet; 2017 Mar; 295(3):697-704. PubMed ID: 28000027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
